Accurate risk prediction for better patient care decisions
The DecisionDx-UM gene expression profile test enables accurate staging of 5-year metastatic risk in uveal melanoma by identifying aggressive tumor biology. The test has been validated in multiple multi-center prospective and retrospective studies and is standard of care in >90% of ocular oncology practices (www.MyUvealMelanoma.com). The 5-year prospective, multi-center, 494-patient study of the Cooperative Ocular Oncology Group (COOG), published in Ophthalmology (Onken et al, 2012) compared DecisionDx-UM to all clinical/pathologic prognostic factors and found it to be superior to, and independent of, all such factors (tumor diameter/thickness, age, histopathology, cytopathology, and chromosome 3 status). The AJCC recommends the test for its "clinically significant" impact on patient care. The DecisionDx-UM test has a high technical success rate averaging 97% in both clinical use and the COOG study.
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about cancer treatment and follow-up care based on the individual molecular signature of their tumor.
Brands: DecisionDx-UM; DecisionDx-Melanoma